Retatrutide is an experimental drug for obesity developed by the American pharmaceutical company Eli Lilly and Company. It is a triple hormone receptor agonist on the GLP-1, GIP, and glucagon receptors.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.